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Abstract:
Movement disorders involVing the basal
ganglia, such as Parkinson's disease,
Huntington's disease andTourette's syn-
drome, arise from altered neurotrans-
mission. Previous studies have demon-
strated variable gene expression ofneu-
ropeptides in striatal neurons following
theincrease or decrease ofdopamine
and/or serotonin transmission. We are
currently employing the technique of
immunocytochemistry to determine
whether increased ordecreased mRNA
levels, induced by altered serotonin
transmission, translate into a correspon-
ding change in neuropeptide levels.
Characterizing thefate ofstriatal neu-
rop.eptide gene products (mRNA and
peptides) may prOVide valuable informa-
tion in developing therapies to treat cer-
tain types ofmovement disorders.
Introduction and Background
The basal ganglia are a group of subcorti-
cal nuclei that are concerned with
extrapyramidal control of motor impulses;
that is, the basal ganglia are responsible
for the planning (inhibition and stimula-
tion) of skeletal muscle activity The basal
ganglia are caudate
nucleus, the putamen, the internal and
external segments of the globus pallidus,
the subthalamic nucleus and the substan-
tia nigra. These nuclei are extensively
interconnected by afferent and efferent
neurons. The caudate nucleus and the
putamen together form the striatum. The
striatum possesses two populations of
neurons. One group contains the neuro-
transmitter GABA and co-localizes the
neuropeptide enkephalin, while the other
group contains GABA and co-localizes the
neuropeptide substance P
Neurons in the basal ganglia form a
complex circuit which work together to
control skeletal muscle movement.
Afferent fibers extend from the cerebral
cortex to the striatum. From there, neu-
rons either follow the indirect or direct
pathway to the thalamus where efferent
fibers extend back to the cerebral cortex.
The subunit of neurons expressing
enkephalin constitutes the indirect path-
way where striatal neurons project to the
external globus pallidus. Signals are sub-
sequently routed through the subthalamic
nucleus, the internal globus pallidus and
then finally to the thalamus. The indirect
pathway orders the inhibition of move-
ment. On the other hand, the direct path-
way is constituted by the subunit of
GABAergicneurons which co-localize
substance P Signals from striatal neurons
forming the direct pathway project to the
internal globus pallidus then directly to
the thalamus. The direct pathway orders
the stimulation of skeletal movement.
These two pathways together send a com-
pleted scheme of planned movement to
the cortex to be processed and sent into
action by the brain stem and spinal cord.
Substance P is generally considered
to act as a potent excitatory neurotrans-
mitter in both the central and peripheral
nervous systems. The application of sub-
stance P to the substantia nigra elicits
strong behavioral responses in live ani-
mals. For example, Stinus et a1., (1978)
demonstrated that substance P can induce
locomotive activity when injected bilater-
ally into the rat tegmental area.
Stimulation of dopanergic cell bodies in
the midbrain with substance P elicited
release of dopamine in the striatum and
nucleus accumbens (Stinus et al., 1978;
Jolicoeur at el, 1980; Elliot et al., 1990).
Additionally; in vivo micro dialysis studies
have demonstrated striatal dopamine
release following infusion of substance P
in the substantia nigra (Herrera-Marschitz
et al., 1986; Barruch et al., 1988; Reid et
al., 1990).
Enkephalin, in direct contrast to sub-
stanceE appears to inhibit release of neu-
rotransmitters from nerve terminals in the
basal ganglia and other regions (Arenas et
al., 1990; Cui et al., 1993; Dewar et a1.,
1986). Enkephalin imparts its physiologi-
cal activity by binding to opioid receptors.
The opioid receptors are located through-
out the body and are responsible for
mediating effects such as analgesia, consti-
pation, muscle relaxation, respiratory
depression, euphoria, nausea and vomit-
ing. Within the striatum, enkephalin and
other opioid peptides elicit mainly
inhibitory properties. Enkephalin inhibits
dopamine stimulation of adenylate cyclase
(Schoffelmeer et a1., 1987) and glutamate-
induced release of acetylcholine from
interneurons (Arenas, et a1., 1990).
Within the globus pallidus, a sub-region
of the basal ganglia, stimulation of opioid
receptors suppresses firing of pallidal neu-
rons (Frey and Huffman, 1985; Napier et
al., 1983).
The production of enkephalin and
subtance P in the striatum are influenced
by a number of neurotransmitters. In
Parkinsons disease, the most significant
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pathological alteration is the idiopathic
loss of neurons in the substantia nigra
causing an overall depletion in striatal
dopamine. In the rat model of Parkinsons
disease, as dopamine decreases, pre-
proenkephalin (enkephalin mRNA)
increases while preprotachykinin (sub-
stance P mRNA) decreases.
In this study, it is hypothesized that
serotonin, another major striatal afferent
system, also plays an important role in
the regulation of basal ganglia neuropep-
tide expression. Although serotonin has
been classified as both an inhibitory and
excitatory neurotransmitter (Bloom et al.,
1972), further investigations have
revealed a more complex nature to this
molecule. Originating from brain stem
raphe cell groups, serotonin is found
within axon terminals distributed in vir-
tually all parts of the central nervous
system (Cooper et al., 1982). Serotonin
functions as a classic neurotransmitter by
altering the polarization of the post-
synaptic membrane, but a yet relatively
unexplored facet of serotonin is its ability
to regulate neurotransmitter I
neuropeptide biosynthesis. This newly
proposed function may result from the
activation of serotonin receptors that can
influence gene expression via second
messenger-linked mechanisms.
Stimulation of serotonin 5HT2
receptors by the drug DOl has been
shown to induce increases in both pre-
proenkephalin and preprotachykinin
(Walker et al., 1996). Therefore, the goal
of the present study is to employ
immunocytochemical techniques to deter-
mine whether these increases in mRNA
translate into corresponding changes in
enkephalin and substance P peptide levels
following 5HT2 receptor activation.
Methods
Tissue Preparation
Whole rat brains fixed in paraformalde-
hyde were purchased from Zivick-Miller
laboratories. Before sectioning, the tissue
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was saturated with a cryoprotectant in
order to prevent ice crystal formation in
the cells. Rat brains were immersed in a
15°;6 sucrose solution, where O.lM phos-
phate buffer saline (PBS) was the solvent,
for 3 days until the tissue was fully satu-
rated. The tissue was then transferred to a
30% sucrose solution for another 3 days.
The tissue was freeze..mounted and
coronally sectioned on an American Optic
Histostat microtome. The tissue was sliced
40 urn thick at -27° C. The sections were
immediately transferred to a petri dish
containing PBSupon slicing.
Immunocytochemistry
This entire process was done by the free-
floating method. The tissue stayed in the
same dish throughout the procedure and
a pipette was used to remove and replace
different solutions in the dish. PBSwas
removed from the dish containing the tis-
sue and 3 ml of O.lM glycine was added.
The tissue incubated in glycine for 30
minutes. Glycine was removed and the
tissue was washed in 3 ml of PBS three
times, five minutes per wash. Tissue was
then soaked in 3 ml of freshly made
0.5°;6 hydrogen peroxide for ten minutes
in order to eliminate endogenous perox-
idase activity: Tissue was washed again
three times, five minutes per wash in
PBS. Tissue was left to incubate for one
hour in 3 ml of 2°;6 blocking serum (1
ml goat serum and 50ml PBS). Next,
the tissue was incubated in 3 ml of
rabbit-anti-enkephalin IgG, 500-fold dilu-
tion, primary antibody for 24 - 48 hours,
covered at 4° C (antibodies are from
Jackson Labs).
After incubation, the tissue was
washed in PBS (same wash time as above).
The tissue was incubated in 3 ml of
biotintylated goat-anti-rabbit IgG, 250-fold
dilution, secondary antibody for one hour
at 4° C. The tissue was washed in PBS and
was then incubated for one hour in
avidin/biotintylated enzyme complex (ABC
kit) from Vector labs at 4° C. The tissue
was washed in PBS again then placed in
3,3'-diaminobenzadine (DAB peroxidase
substrate tablet set from Sigma Chemicals)
for five minutes. The tissue was washed
for a final time in PBSand mounted and
fixed on glass slides for viewing.
Results
There appears to be light immunoreactivi-
ty corresponding to the region of the basal
ganglia for enkephalin and similarly for
substance P Therefore, the immuno-
cytochemical staining techniques for the
detection of enkephalin and substance P
neuropeptides in the basal ganglia have
been established. These techniques are
now ready for the application to drug
treated animals in our laboratories.
Discussion
Our results are supported by the findings
of other researchers in this area of study;
therefore, they are not surprising.
However, if we find that neuropeptide
products increase with increased mRNA,
serotonin may prove to be a means to
treat basal ganglia disorders. Insight on
the role of serotonin in the regulation of
basal ganglia neuropeptide expression
can provide useful information in the
engineering of new drugs and therapies.
Since the 5HT pathways remain relatively
intact and are not subject to as severe
degree of cell loss as the substantia nigra
dopamine system, perhaps serotonin can
offer an alternate approach to treat these
movement disorders. Serotonin may have
the potential to be used in conjunction
with, or maybe even apart from the
current practice of dopamine replacement
therapy in Parkinson's disease patients.
This study may uncover new mechanisms
to regulate striatal gene expression. At the
very least, a greater understanding of
basal ganglia disorders on a molecular
level will be achieved.
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